Two years experience with recombinant Human DNase I in the treatment of pulmonary disease in cystic fibrosis
- 31 August 1995
- journal article
- clinical trial
- Published by Elsevier in Respiratory Medicine
- Vol. 89 (7) , 499-502
- https://doi.org/10.1016/0954-6111(95)90126-4
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994
- Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosisThe Lancet, 1993
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993
- Prediction of Mortality in Patients with Cystic FibrosisNew England Journal of Medicine, 1992
- A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic FibrosisNew England Journal of Medicine, 1992
- Lung Function Testing: Selection of Reference Values and Interpretative StrategiesAmerican Review of Respiratory Disease, 1991
- Standardization of Spirometry—1987 UpdateAmerican Review of Respiratory Disease, 1987
- Cystic fibrosis in adolescents and adults.Thorax, 1987
- A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosisEuropean Journal of Pediatrics, 1985
- Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis.Thorax, 1980